Mgen Solutions

At a glance

Mgen Solutions filed 136 disclosures in the last 12 months, including 14 5% holder, 5 issuance and 1 insider. The most recent key filing was on Oct 22: A major holder's stake fell from 20.00% to 16.01% (pledge).

Revenue for 2025 was ₩28.6B, down 17.1% on 2024. It made an operating loss of ₩10.3B. Debt was 78% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩9B and operating loss of ₩6.7B.

The 2025 annual report lists 91 employees with an average tenure of 4.8 years and average pay of ₩55.1M, #1444 of 2,191 listed companies by average pay. Its 7 directors and auditors were paid ₩73M each on average. It paid no cash dividend for 2025. 트렌스젠바이오(주) and related parties held 18.78% at year end.

Of 5 recent 5%+ holder reports, 3 raised and 2 cut a stake; the largest stake reported was 20.00% on Jun 29.

From the 2025 annual report

Staff: 91 (74 men, 17 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩4.9B. Directors and auditors: 7, paid ₩514M in total.

No cash dividend was paid for 2025.

Largest shareholder

트렌스젠바이오(주) holds 10.65%; with 4 related parties the group holds 18.78% of common shares at year end (from 13.08% at the start of the year).

Auditor: 삼일회계법인 · opinion: Unqualified. The report includes an emphasis of matter.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports